Digital mental health care: five lessons from Act 1 and a preview of Acts 2-5.

Digital tools are transforming mental health care. The promise of this transformation to improve outcomes has not yet been realized fully. While some have become skeptical, this article argues that we are just at the end of Act 1, with several opportunities and challenges ahead.

The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression.

This article is a clinical guide which discusses the "state-of-the-art" usage of the classic monoamine oxidase inhibitor (MAOI) antidepressants (phenelzine, tranylcypromine, and isocarboxazid) in modern psychiatric practice. The guide is for all clinicians, including those who may not be experienced MAOI prescribers. It discusses indications, drug-drug interactions, side-effect management, and the safety of various augmentation strategies.

Mental health care 2.0.

While the COVID-19 pandemic has been a burden for our mental health, it also led to a surge in mental health care innovation. Appointments by telephone or video, as well as web- and app-based tools, have become part of a digital mental health revolution. Last year, US venture capitalists invested $5.

The AURORA Study: a longitudinal, multimodal library of brain biology and function after traumatic stress exposure.

Adverse posttraumatic neuropsychiatric sequelae (APNS) are common among civilian trauma survivors and military veterans. These APNS, as traditionally classified, include posttraumatic stress, postconcussion syndrome, depression, and regional or widespread pain. Traditional classifications have come to hamper scientific progress because they artificially fragment APNS into siloed, syndromic diagnoses unmoored to discrete components of brain functioning and studied in isolation.